Clinical Trial Update: Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy

View source ↗

Summary

Real-world study assessing effectiveness and safety of first-line nivolumab plus ipilimumab versus nivolumab monotherapy (after prior therapy) in patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Renal Cell Carcinoma | Status: COMPLETED